Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth ...
Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback